Clinical Trial Update: Impact of Recombinant Human Growth Hormone on HIV Persistence [Phase 2]

View source ↗

Summary

Phase 2 trial investigates the effect of recombinant human growth hormone on HIV persistence. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Recombinant human growth hormone (somatropin)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Human Immunodeficiency Virus, Growth Hormone Treatment | Phase 2 | Status: COMPLETED